Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A structure-function study of ligand recognition by CD22beta.

S M van Rossenberg1, L A Sliedregt, R Autar

  • 1Leiden/Amsterdam Center for Drug Research, Division of Biopharmaceutics, Sylvius Laboratories, Leiden University, 2300 RA Leiden, The Netherlands. rossenbe@lacdr.leidenuniv.nl

The Journal of Biological Chemistry
|January 21, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to immunopeptidomics analysis of human atherosclerosis plaques identifies antigenic drivers of atherosclerosis[Atherosclerosis, (409), October 2025, 120509].

Atherosclerosis·2026
Same author

Immunopeptidomics analysis of human atherosclerosis plaques identifies antigenic drivers of atherosclerosis.

Atherosclerosis·2025
Same author

Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study.

Frontiers in immunology·2022
Same author

Intrathecal morphine in combination with bupivacaine as pre-emptive analgesia in posterior lumbar fusion surgery: a retrospective cohort study.

Journal of orthopaedic surgery and research·2022
Same author

Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases.

Journal of internal medicine·2020
Same author

Reply to "Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner".

Atherosclerosis·2018
Same journal

Isotope-Edited ESEEM: A New Method for Probing Copper Binding Sites in Neurodegenerative Proteins.

The Journal of biological chemistry·2026
Same journal

Introduction to the Thematic Review Series on Intracellular Protein Degradation. The ubiquitous biology of intracellular protein degradation: a tribute to Alfred L. ("Fred") Goldberg.

The Journal of biological chemistry·2026
Same journal

Correction: Aromatic residue-rich amino-terminal segments of temporin L self-assemble into collagen-mimetic peptides with cell-adhesion properties.

The Journal of biological chemistry·2026
Same journal

YhbO is a DJ-1 family glyoxalase and α-oxoaldehyde hydratase that confers resistance to reactive carbonyl stress (112).

The Journal of biological chemistry·2026
Same journal

ARMH3 acts as a central scaffold at the Golgi/TGN through interactions with Arl5, GBF1, and PI4KB.

The Journal of biological chemistry·2026
Same journal

PAX8 controls proximal tubule epithelial identity and stress response through epigenetic modification of distal regulatory elements.

The Journal of biological chemistry·2026
See all related articles

Researchers developed potent CD22 antagonists by modifying carbohydrate ligands. The most effective compound, a trivalent cluster, showed a 300-fold affinity increase, offering potential for targeted drug delivery in B-cell related diseases.

Area of Science:

  • Biochemistry
  • Immunology
  • Medicinal Chemistry

Background:

  • CD22 is a B-cell-specific adhesion molecule that binds sialic acid-containing glycans.
  • CD22 engagement by endogenous ligands promotes B-cell activation and proliferation.
  • High-affinity CD22 ligands could serve as inhibitors for B-cell mediated inflammatory diseases.

Purpose of the Study:

  • To investigate the structural requirements for CD22 ligand binding.
  • To synthesize and screen novel CD22 ligands with enhanced affinity.
  • To evaluate the potential of potent CD22 ligands as targeted therapeutic agents.

Main Methods:

  • Synthesis of a library of 20 mono-, di-, and trisaccharide analogs of Neu5Ac(alpha2,6)Lac.
  • Screening of synthesized analogs for binding affinity to CD22beta.

Related Experiment Videos

  • Generation of multivalent ligands using glutamate or Tris cluster cores.
  • Affinity assessment of monovalent and multivalent ligands using fluorescence-activated cell sorting (FACS).

    • Main Results:

    • CD22 ligand recognition showed tolerance to modifications on the anomeric sugar.
    • A nitro aromatic group at C-2 enhanced ligand affinity.
    • Multivalent ligands exhibited at least a 10-fold increase in affinity compared to monovalent forms.
    • A trivalent Tris-based cluster of Neu5Ac-4-nitrobenzoyl-Glc demonstrated a 300-fold higher affinity, representing the most potent CD22 antagonist to date.
    • Efficient cellular uptake of a CD22 substrate was confirmed via in vitro FACS studies.

    Conclusions:

    • Structural modifications, particularly the addition of a nitro aromatic group, can significantly enhance CD22 ligand affinity.
    • Multivalency, especially bivalency, effectively increases ligand affinity for CD22.
    • The synthesized potent CD22 antagonist holds promise for targeted delivery of immunomodulatory drugs and cytostatics.